LEXICON PHARMACEUTICALS, INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
LEXICON PHARMACEUTICALS, INC. (LXRX) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $2.99 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-06
- 2026-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2.99M.
- 2026-03-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3.20M.
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3.41M.
- 2025-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3.63M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $2.99M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $3.20M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $3.41M 10-K · filed 2026-03-05 |
| 2025-09-30 | $3.63M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $2.56M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $2.70M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $2.83M 10-K · filed 2025-03-07 |
| 2024-09-30 | $2.98M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $3.12M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $3.28M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $3.43M 10-K · filed 2024-03-25 |
| 2023-09-30 | $3.59M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $3.75M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $3.92M 10-Q · filed 2023-05-04 |
| 2022-09-30 | $4.24M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $237.00K 10-Q · filed 2022-08-03 |
| 2022-03-31 | $281.00K 10-Q · filed 2022-05-05 |
| 2021-09-30 | $386.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $444.00K 10-Q · filed 2021-08-06 |
| 2021-03-31 | $505.00K 10-Q · filed 2021-05-06 |
| 2019-09-30 | $281.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $322.00K 10-Q · filed 2019-08-01 |
| 2019-03-31 | $366.00K 10-Q · filed 2019-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |